Table 2.
Summary of immunological markers of blood-heat syndrome.
| Source | Markers used ELISA measurement methods, mean (SD) | ||||||
|---|---|---|---|---|---|---|---|
| IFN-γ (pg/mL) | IL-4 (pg/mL) | IL-17 (pg/mL) | IL-23 (pg/mL) | IL-6 (pg/mL) | TNF-α (pg/mL) | IL-10 (pg/mL) | |
| Cao et al. [10] | Control 47.44 (21.46); psoriasis 91.20 (48.37) |
Control 47.41 (14.26); psoriasis 32.73 (7.90) |
Control 49.15 (31.18); psoriasis 60.30 (48.08) |
||||
|
| |||||||
| Chen et al. [11] | Control 46.00 (0.67); psoriasis 86.48 (46.44) |
Control 48.45 (13.63); psoriasis 32.52 (8.13) |
|||||
|
| |||||||
| Chen and Yang [23] | Control 20.70 (13.20); psoriasis 81.40 (15.10) |
Control 201.00 (78.00); psoriasis 529.00 (202.00) |
|||||
|
| |||||||
| Fan et al. [12] | Control 2.85 (0.64); psoriasis 7.32 (2.01) |
Control 814.93 (372.51); psoriasis 1491.80 (464.36) |
Control 109.32 (7.22); psoriasis 418.05 (108.83) |
||||
|
| |||||||
| He et al. [13] | Control 30.07 (3.36); psoriasis 11.29 (3.70) |
Control 7.40 (1.56); psoriasis 30.58 (7.14) |
|||||
|
| |||||||
| Hu and Yang [24] | Control 8.72 (2.04); psoriasis 24.10 (8.13) |
Control 30.21 (3.40); psoriasis 19.89 (1.19) |
Control 74.30 (24.14); psoriasis 130.26 (21.99) |
||||
|
| |||||||
| Li [14] | Control 69.16 (29.99); psoriasis 98.68 (49.65) |
Control 86.65 (41.26); psoriasis 131.24 (41.24) |
Control 85.73 (27.96); psoriasis 105.60 (35.27) |
||||
|
| |||||||
| Li [15] | Control 6.43 (0.33); psoriasis 15.29 (0.49) |
Control 18.25 (1.44); psoriasis 6.51 (0.97) |
|||||
|
| |||||||
| Lin et al. [16] | Control 8.72 (2.06); psoriasis 24.10 (7.84) |
Control 21.27 (4.80); psoriasis 8.59 (4.97) |
|||||
|
| |||||||
| Liu [17] | Control 10.86 (5.41); psoriasis 14.19 (6.84) |
Control 67.65 (17.01); psoriasis 63.69 (20.23) |
Control 46.89 (9.13); psoriasis 55.43 (13.76) |
Control 24.39 (7.57); psoriasis 16.84 (6.74) |
|||
|
| |||||||
| Liu et al. [18] | Control 6.24 (1.66); psoriasis 23.37 (2.40) |
Control 6.95 (0.83); psoriasis 23.12 (1.89) |
|||||
|
| |||||||
| Sun and Zho [19] | Control 8.63 (0.88); psoriasis 11.37 (2.80) |
Control 21.65 (1.53); psoriasis 39.44 (6.11) |
|||||
|
| |||||||
| Wu et al. [25] | Control 46.69 (11.43); psoriasis 114.60 (19.78) |
Control 24.39 (2.27); psoriasis 14.14 (1.62) |
|||||
|
| |||||||
| Zhang [20] | Control 7.37 (0.85); psoriasis 26.67 (17.78) |
||||||
|
| |||||||
| Zhang et al. [21] | Control 8.59 (2.59); psoriasis 11.50 (4.48) |
Control 78.20 (43.00); psoriasis 239.06 (159.11) |
Control 6.5 (3.1); psoriasis 12.8 (7.4) |
||||
|
| |||||||
| Zhou [22] | Control 71.43 (45.90); psoriasis 244.41 (133.25) |
Control 5.9 (3.4); psoriasis 11.3 (7.8) |
|||||
|
| |||||||
| Zhou and Wang [26] | Control 33.34 (4.50); psoriasis 96.14 (12.29) |
Control 25.91 (3.69); psoriasis 12.88 (2.66) |
Control 8.09 (1.06); psoriasis 32.64 (6.23) |
Control 21.96 (3.16); psoriasis 12.77 (2.70) |
|||
ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.